Exchange Traded Concepts LLC Grows Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Exchange Traded Concepts LLC raised its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 63.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 311,846 shares of the company's stock after buying an additional 120,572 shares during the period. Exchange Traded Concepts LLC owned about 0.54% of Ginkgo Bioworks worth $1,778,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new stake in Ginkgo Bioworks in the 4th quarter valued at about $29,000. Barclays PLC raised its holdings in shares of Ginkgo Bioworks by 353.6% in the 4th quarter. Barclays PLC now owns 54,166 shares of the company's stock valued at $531,000 after purchasing an additional 42,224 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Ginkgo Bioworks by 15.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,995 shares of the company's stock valued at $412,000 after purchasing an additional 5,746 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Ginkgo Bioworks by 65.1% in the 4th quarter. Renaissance Technologies LLC now owns 114,654 shares of the company's stock valued at $1,126,000 after purchasing an additional 45,200 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Ginkgo Bioworks in the 4th quarter valued at about $665,000. 78.63% of the stock is owned by hedge funds and other institutional investors.

Ginkgo Bioworks Stock Performance

NYSE:DNA opened at $8.59 on Wednesday. Ginkgo Bioworks Holdings, Inc. has a one year low of $5.00 and a one year high of $18.40. The firm has a market cap of $502.48 million, a P/E ratio of -0.94 and a beta of 1.25. The firm has a 50-day simple moving average of $7.71 and a 200-day simple moving average of $9.09.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 198.84% and a negative return on equity of 52.35%. The business had revenue of $48.32 million during the quarter, compared to the consensus estimate of $38.70 million. On average, research analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.

Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.